Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.97 [0.82, 1.15] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.60 [1.33, 1.92] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | important | - |
DCR | 0.60 [0.39, 0.94] | | > 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
events or deaths (EFS) | 0.63 [0.43, 0.93] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 0.89 [0.53, 1.50] | | > 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
pCR | 13.60 [6.77, 27.33] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.25 [0.01, 4.74] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.35 [1.01, 1.80] | | < 1 | | 0% | 1 study (1/-) | 2.2 % | NA | not evaluable | | non important | - |
SAE (any grade) | 0.99 [0.66, 1.48] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.25 [0.03, 2.00] | | < 1 | | 0% | 1 study (1/-) | 90.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.61 [0.14, 2.59] | | < 1 | | 97% | 2 studies (2/-) | 74.9 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 1.01 [0.42, 2.40] | | < 1 | | 0% | 2 studies (2/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.72 [0.89, 3.31] | | < 1 | | 52% | 2 studies (2/-) | 5.4 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 5.06 [0.57, 44.81] | | < 1 | | 0% | 2 studies (2/-) | 7.4 % | low | not evaluable | high | non important | - |
Alopecia TRAE (grade 3-4) | 0.87 [0.37, 2.05] | | < 1 | | 0% | 2 studies (2/-) | 62.2 % | low | not evaluable | high | non important | - |
Anaemia TRAE (grade 3-4) | 0.68 [0.16, 2.95] | | < 1 | | 80% | 2 studies (2/-) | 69.8 % | low | not evaluable | high | non important | - |
Asthenia TRAE (grade 3-4) | 1.37 [0.69, 2.72] | | < 1 | | 0% | 2 studies (2/-) | 18.6 % | low | not evaluable | high | non important | - |
Colitis TRAE (grade 3-4) | 2.02 [0.34, 12.03] | | < 1 | | 0% | 2 studies (2/-) | 22.2 % | low | not evaluable | high | non important | - |
Constipation TRAE (grade 3-4) | 0.48 [0.04, 6.30] | | < 1 | | 0% | 2 studies (2/-) | 70.9 % | some concern | not evaluable | moderate | non important | - |
Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.02 [0.34, 12.03] | | < 1 | | 0% | 2 studies (2/-) | 22.2 % | low | not evaluable | high | non important | - |
Diabetes TRAE (grade 3-4) | 1.32 [0.17, 10.43] | | < 1 | | 0% | 2 studies (2/-) | 39.8 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.69 [0.10, 4.85] | | < 1 | | 78% | 2 studies (2/-) | 64.5 % | low | not evaluable | high | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.86 [0.85, 4.05] | | < 1 | | 0% | 2 studies (2/-) | 6.0 % | low | not evaluable | high | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.31 [0.01, 6.85] | | < 1 | | 79% | 2 studies (2/-) | 76.6 % | low | not evaluable | high | non important | - |
Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 9.06 [0.52, 156.66] | | < 1 | | 0% | 1 study (1/-) | 6.7 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.50 [0.13, 17.05] | | < 1 | | 0% | 2 studies (2/-) | 37.4 % | low | not evaluable | high | non important | - |
Hypophysitis TRAE (grade 3-4) | 8.04 [0.46, 140.38] | | < 1 | | 0% | 1 study (1/-) | 7.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 2.45 [0.26, 23.20] | | < 1 | | 0% | 2 studies (2/-) | 21.9 % | low | not evaluable | high | non important | - |
Increase AST TRAE (grade 3-4) | 3.49 [0.75, 16.21] | | < 1 | | 45% | 2 studies (2/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 2.30 [1.14, 4.63] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | low | not evaluable | high | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 2.53 [0.86, 7.45] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.45 [0.07, 2.70] | | < 1 | | 50% | 2 studies (2/-) | 80.9 % | low | not evaluable | high | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 2.32 [0.21, 25.15] | | < 1 | | 0% | 2 studies (2/-) | 24.6 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 2.33 [0.92, 5.88] | | < 1 | | 0% | 2 studies (2/-) | 3.8 % | low | not evaluable | high | non important | - |
Nephritis TRAE (grade 3-4) | 3.49 [0.34, 35.41] | | < 1 | | 0% | 2 studies (2/-) | 14.7 % | low | not evaluable | high | non important | - |
Neutropenia TRAE (grade 3-4) | 0.11 [0.00, 13.86] | | < 1 | | 92% | 2 studies (2/-) | 80.8 % | low | not evaluable | high | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 4.00 [0.21, 75.85] | | < 1 | | 0% | 1 study (1/-) | 18.1 % | NA | not evaluable | | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.88 [0.62, 5.72] | | < 1 | | 0% | 1 study (1/-) | 13.2 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 0.72 [0.13, 4.06] | | < 1 | | 37% | 2 studies (2/-) | 64.7 % | low | not evaluable | high | non important | - |
Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.44 [0.40, 14.85] | | < 1 | | 0% | 2 studies (2/-) | 16.8 % | low | not evaluable | high | non important | - |
Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 2.39 [0.45, 12.62] | | < 1 | | 0% | 2 studies (2/-) | 15.4 % | low | not evaluable | high | non important | - |
Rash TRAE (grade 3-4) | 3.51 [0.43, 28.62] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Sarcoidosis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 6.06 [0.78, 46.96] | | < 1 | | 42% | 2 studies (2/-) | 4.3 % | low | not evaluable | high | non important | - |
Stomatitis TRAE (grade 3-4) | 2.64 [0.12, 57.65] | | < 1 | | 49% | 2 studies (2/-) | 27.1 % | low | not evaluable | high | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.50 [0.13, 17.05] | | < 1 | | 0% | 2 studies (2/-) | 37.4 % | low | not evaluable | high | non important | - |
Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.51 [0.59, 3.82] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |